Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-targeted CAR-T Cell Therapy for Minimal Residual Disease in B-cell Malignancies After Autologous Stem Cell Transplantation

NCT03564977 is registered in ClinicalTrials.gov with Qingdao Central Hospital as lead sponsor.

NCT NCT03564977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03564977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-targeted CAR-T Cell Therapy for Minimal Residual Disease in B-cell Malignancies After Autologous Stem Cell Transplantation
Lead sponsor
Qingdao Central Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
July 15, 2018
Completion date
June 15, 2020
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, b-cell, lymphoma, b-cell, minimal disease, residual